Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Case Report Describes Possible Betahistine–Suicidality Link
A single case report described suicidal ideation that resolved after betahistine discontinuation and recurred after rechallenge, but the findings cannot establish causality or quantify risk.
Clinical Report: Case Report Describes Possible Betahistine–Suicidality Link
Overview
This case report describes a potential association between betahistine use and the emergence of depressive symptoms with suicidal ideation in a 33-year-old male patient.
Background
Betahistine is commonly used for treating vertigo and Ménière disease, despite not being FDA-approved. With over 100 million estimated patient exposures globally, understanding its safety profile, particularly concerning suicidality, is critical for clinicians. This case report highlights a previously unreported potential link between betahistine and suicidality.
Data Highlights
No numerical or trial data presented in the article.
Key Findings
A 33-year-old male developed low mood and suicidal ideation after starting betahistine.
Symptoms resolved within 2 days after discontinuation of betahistine.
The case was classified as a probable adverse drug reaction based on established assessment scales.
Prior safety signals indicated betahistine as a risk factor for suicide attempts.
Clinical Implications
Clinicians should be aware of the potential for neuropsychiatric adverse reactions in patients treated with betahistine.
Conclusion
This case report presents a potential psychiatric side effect associated with betahistine.
Dizziness is one of the most common yet complex complaints encountered across primary care, neurology, otolaryngology, and cardiology. It can present as vertigo, imbalance, or nonspecific lightheadedness. It can leave both patients and physicians searching for clear answers.
